A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Investigational new drugs

• Publication date

  2012-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s10637-011-9687-4PMID 21594619
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cancer Statistics, 2009

  2010cited by this paper
• Literature Review October–December 2008

  2009cited by this paper
• Back to basics: explaining sample size in outcome trials, are statisticians doing a thorough job?

  2009influential reference
• Cancer Statistics, 2009

  2009cited by this paper
• Phase II Study of Docetaxel and Gefitinib as Second-Line Therapy in Gemcitabine Pretreated Patients with Advanced Pancreatic Cancer

  2009influential reference
• Second-Line Therapy in Refractory Pancreatic Cancer. Results of a Phase II Study

  2009cited by this paper
• Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer.

  2009cited by this paper
• Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.

  2008influential reference
• Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second‐line therapy for patients with advanced pancreatic cancer

  2008cited by this paper
• A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study

  2008cited by this paper
• Biological Characterization of ARRY-142886 (AZD6244), a Potent, Highly Selective Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor

  2007cited by this paper
• Irinotecan monotherapy as second-line treatment in advanced pancreatic cancer

  2007cited by this paper
• Clinical experience of MEK inhibitors in cancer therapy.

  2007cited by this paper
• Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer.

  2007cited by this paper
• A Multicenter Phase II Study of Docetaxel in Combination with Gefitinib in Gemcitabine-Pretreated Patients with Advanced/Metastatic Pancreatic Cancer

  2007influential reference
• Recent advances of MEK inhibitors and their clinical progress.

  2007cited by this paper
• Second-line chemotherapy in advanced pancreatic carcinoma: a multicenter survey of the Gruppo Oncologico Italia Meridionale on the activity and safety of the FOLFOX4 regimen in clinical practice.

  2007cited by this paper
• Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study

  2006cited by this paper
• Novel targets in solid tumors: MEK inhibitors.

  2006cited by this paper
• Second-line chemotherapy with pemetrexed after gemcitabine failure in patients with advanced pancreatic cancer: a multicenter phase II trial.

  2006cited by this paper
• Estimates of the cancer incidence and mortality in Europe in 2006.

  2006cited by this paper
• Phase II trial of neoadjuvant vincristine, ifosfamide, and doxorubicin with granulocyte colony-stimulating factor support in children and adolescents with advanced-stage nonrhabdomyosarcomatous soft tissue sarcomas: a Pediatric Oncology Group Study.

  2005cited by this paper
• Oxaliplatin for Pretreated Patients with Advanced or Metastatic Pancreatic Cancer: A Multicenter Phase II Study

  2005cited by this paper
• Oxaliplatin/folinic acid/5-fluorouracil [24h] (OFF) plus best supportive care versus best supportive care alone (BSC) in second-line therapy of gemcitabine-refractory advanced pancreatic cancer (CONKO 003)

  2005cited by this paper
• Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study

  2005cited by this paper
• Design issues of randomized phase II trials and a proposal for phase II screening trials.

  2005cited by this paper
• Cancer Facts & Figures 2004

  2004cited by this paper
• Combined Irinotecan and Oxaliplatin in Patients with Advanced Pre-Treated Pancreatic Cancer

  2004cited by this paper
• Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma

  2003cited by this paper
• Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer.

  2002cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors

  2000influential reference
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000cited by this paper
• Paclitaxel as weekly second-line therapy in patients with advanced pancreatic carcinoma

  2000cited by this paper
• KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas.

  1988cited by this paper
• Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes.

  1988cited by this paper

• Role of ERK1/2 and p38 Protein Kinases in Tumors: Biological Insights and Clinical Implications.

  2025cites this paper
• Treatment of KRAS-Mutated Pancreatic Cancer: New Hope for the Patients?

  2025cites this paper
• Blood-based biomarkers in pancreatic ductal adenocarcinoma: developments over the last decade and what holds for the future- a review

  2025cites this paper
• Combination therapy of avutometinib and MRTX1133 synergistically suppresses cell growth by inducing apoptosis in KRASG12D-mutated pancreatic cancer.

  2025cites this paper
• KRAS: the Achilles’ heel of pancreas cancer biology

  2025cites this paper
• PLK1 blockade enhances the anti-tumor effect of MAPK inhibition in pancreatic ductal adenocarcinoma.

  2025cites this paper
• Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibition in Patients With Metastatic Pancreatic Cancer.

  2025cites this paper
• “Undruggable KRAS”: druggable after all

  2024cites this paper
• Consensus, debate, and prospective on pancreatic cancer treatments

  2024cites this paper
• Separable cell cycle arrest and immune response elicited through pharmacological CDK4/6 and MEK inhibition in RASmut disease models.

  2024cites this paper
• Cannabigerol Induces Autophagic Cell Death by Inhibiting EGFR-RAS Pathways in Human Pancreatic Ductal Adenocarcinoma Cell Lines

  2024cites this paper
• CRISPRing KRAS: A Winding Road with a Bright Future in Basic and Translational Cancer Research

  2024cites this paper
• Selumetinib—A Comprehensive Review of the New FDA-Approved Drug for Neurofibromatosis

  2024cites this paper
• Exploring the Horizon: Anti-Fibroblast Growth Factor Receptor Therapy in Pancreatic Cancer with Aberrant Fibroblast Growth Factor Receptor Expression—A Scoping Review

  2024cites this paper
• Genetic and therapeutic landscapes in cohort of pancreatic adenocarcinomas: next-generation sequencing and machine learning for full tumor exome analysis

  2024cites this paper
• Unveiling the Promise: Navigating Clinical Trials 1978–2024 for PDAC

  2024cites this paper
• Inhibition of the RAF/MEK/ERK Signaling Cascade in Pancreatic Cancer: Recent Advances and Future Perspectives

  2024cites this paper
• Quantitative Live Imaging Reveals Phase Dependency of PDAC Patient‐Derived Organoids on ERK and AMPK Activity

  2024cites this paper
• Concurrent inhibition of pBADS99 synergistically improves MEK inhibitor efficacy in KRASG12D-mutant pancreatic ductal adenocarcinoma

  2024cites this paper
• Molecular Classification and Pathogenesis of Pancreatic Adenocarcinoma and Targeted Therapies: A Review.

  2024cites this paper
• Evaluation of KRAS inhibitor-directed therapies for pancreatic cancer treatment

  2024cites this paper
• Mucocutaneous toxicities from MEK inhibitors: a scoping review of the literature

  2024cites this paper
• Targeting KRAS in Pancreatic Ductal Adenocarcinoma: The Long Road to Cure

  2023cites this paper
• Novel strategy for oncogenic alteration-induced lipid metabolism reprogramming in pancreatic cancer

  2023cites this paper
• The KRAS signaling pathway's impact on the characteristics of pancreatic cancer cells.

  2023cites this paper
• Personalized matched targeted therapy in advanced pancreatic cancer: a pilot cohort analysis

  2023cites this paper
• Ornithine aminotransferase supports polyamine synthesis in pancreatic cancer

  2023cites this paper
• Scaffolding Protein Connector Enhancer of Kinase Suppressor of Ras 1 (CNKSR1) Regulates MAPK Inhibition Responsiveness in Pancreas Cancer via Crosstalk with AKT Signaling

  2023cites this paper
• A Novel 3DNA® Nanocarrier effectively delivers payloads to pancreatic tumors.

  2023cites this paper
• Recent advances in targeted therapy for pancreatic adenocarcinoma

  2023cites this paper
• Targeting KRAS for the potential treatment of pancreatic ductal adenocarcinoma: Recent advancements provide hope (Review)

  2023influential citation
• CDK7 inhibition augments response to multidrug chemotherapy in pancreatic cancer

  2022cites this paper
• Emerging kinase inhibitors for the treatment of pancreatic ductal adenocarcinoma

  2022cites this paper
• KRAS pathway-based therapeutic approaches in pancreatic cancer.

  2022cites this paper
• Moving towards dawn: KRas signaling and treatment in pancreatic ductal adenocarcinoma.

  2022cites this paper
• Targeting RAS mutants in malignancies: successes, failures, and reasons for hope

  2022cites this paper
• Targeting KRAS in Pancreatic Cancer

  2022cites this paper
• Selumetinib: a selective MEK1 inhibitor for solid tumor treatment

  2022cites this paper
• The Next Frontier in Pancreatic Cancer: Targeting the Tumor Immune Milieu and Molecular Pathways

  2022cites this paper
• Targeting the ERK mitogen-activated protein kinase cascade for the treatment of KRAS-mutant pancreatic cancer.

  2022cites this paper
• AP1/Fra1 confers resistance to MAPK cascade inhibition in pancreatic cancer

  2022cites this paper
• Disassembly of embryonic keratin filaments promotes pancreatic cancer metastases

  2022cites this paper
• KRAS Mutation Variants and Co-occurring PI3K Pathway Alterations Impact Survival for Patients with Pancreatic Ductal Adenocarcinomas

  2022cites this paper
• Pancreatic adenocarcinoma: molecular drivers and the role of targeted therapy

  2021cites this paper
• Phase II study of selumetinib, an orally active inhibitor of MEK1 and MEK2 kinases, in KRASG12R-mutant pancreatic ductal adenocarcinoma

  2021cites this paper
• The State-of-the-Art of Phase II/III Clinical Trials for Targeted Pancreatic Cancer Therapies

  2021cites this paper
• Mutations in key driver genes of pancreatic cancer: molecularly targeted therapies and other clinical implications

  2021cites this paper
• Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges

  2021cites this paper
• CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment

  2021cites this paper
• Personalizing Medicine With Germline and Somatic Sequencing in Advanced Pancreatic Cancer: Current Treatments and Novel Opportunities.

  2021cites this paper
• Emerging RAS-directed therapies for cancer

  2021cites this paper
• Systemic therapy in metastatic pancreatic adenocarcinoma: current practice and perspectives

  2021cites this paper
• Prognostic factors in advanced pancreatic ductal adenocarcinoma patients-receiving second-line treatment: a single institution experience

  2021cites this paper
• Anti-Tumor Effects of MAPK-Dependent Tumor-Selective Oncolytic Vaccinia Virus Armed with CD/UPRT against Pancreatic Ductal Adenocarcinoma in Mice

  2021cites this paper
• KRAS mutation in pancreatic cancer.

  2021cites this paper
• Advances in Targeted Therapy and Immunotherapy for Pancreatic Cancer.

  2021cites this paper
• Phase I study of cediranib, an oral VEGFR inhibitor, in combination with selumetinib, an oral MEK inhibitor, in patients with advanced solid malignancies

  2021cites this paper
• Clinical Pharmacokinetics and Pharmacodynamics of Selumetinib

  2020cites this paper
• Regulation of metabolic reprogramming by tumor suppressor genes in pancreatic cancer

  2020cites this paper
• FOLFIRINOX in pancreatic cancer: from state of the art treatments to promising translational studies for personalized therapy

  2020cites this paper
• Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma

  2020cites this paper
• RAS-targeted therapies: is the undruggable drugged?

  2020cites this paper
• KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities

  2020cites this paper
• ERK2 Phosphorylates PFAS to Mediate Posttranslational Control of De Novo Purine Synthesis.

  2020cites this paper
• Beyond the Genomic Mutation: Rethinking the Molecular Biomarkers of K-RAS Dependency in Pancreatic Cancers

  2020cites this paper
• Cellular Plasticity in Breast Cancer Progression and Therapy

  2020cites this paper
• Pancreatic Cancer and Its Microenvironment—Recent Advances and Current Controversies

  2020cites this paper
• Targeting the MAPK Pathway in KRAS-Driven Tumors.

  2020cites this paper
• Molecular Biomarkers of K-RAS Dependency

  2020cites this paper
• Targeting dual signalling pathways in concert with immune checkpoints for the treatment of pancreatic cancer

  2020cites this paper
• Small molecule inhibitors in pancreatic cancer.

  2020cites this paper
• Signaling adaptor protein Crk is involved in malignant feature of pancreatic cancer associated with phosphorylation of c-Met.

  2020cites this paper
• Pancreatic Adenocarcinoma: Unconventional Approaches for an Unconventional Disease

  2020cites this paper
• SETD5-Coordinated Chromatin Reprogramming Regulates Adaptive Resistance to Targeted Pancreatic Cancer Therapy.

  2020cites this paper
• Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer

  2020cites this paper
• Investigating the potential clinical benefit of Selumetinib in resensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy (SEL-I-METRY): protocol for a multicentre UK single arm phase II trial

  2019cites this paper
• Genomic profiling in pancreatic ductal adenocarcinoma and a pathway towards therapy individualization: A scoping review.

  2019cites this paper
• Novel Targeted Treatment Approaches in Pancreatic Cancer

  2019cites this paper
• Targeting dual signaling pathways in concert with immune checkpoints for the treatment of pancreatic cancer

  2019cites this paper
• Small molecule tyrosine kinase inhibitors and pancreatic cancer-Trials and troubles.

  2019cites this paper
• Inhibition of HSP90 overcomes resistance to chemotherapy and radiotherapy in pancreatic cancer

  2019cites this paper
• New therapeutic targets in pancreatic cancer.

  2019cites this paper
• Prognostic implications of RAS alterations in diverse malignancies and impact of targeted therapies

  2019cites this paper
• The evaluation of efficacy and tolerability of gemcitabine vs. capecitabine therapy in the second-line setting for metastatic pancreatic cancer patients with poor performance status

  2019cites this paper
• Up-to-Date Tailored Systemic Treatment in Pancreatic Ductal Adenocarcinoma

  2019cites this paper
• Precision medicine based on next-generation sequencing and master controllers

  2018cites this paper
• Molecularly Targeted Therapies in Pancreatic Cancer

  2018cites this paper
• Targeted Therapies for Pancreatic Cancer

  2018cites this paper
• New Horizons in the Treatment of Metastatic Pancreatic Cancer: A Review of the Key Biology Features and the Most Recent Advances to Treat Metastatic Pancreatic Cancer

  2018cites this paper
• Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC)

  2018cites this paper
• Current status and dilemma of second-line treatment in advanced pancreatic cancer: is there a silver lining?

  2018cites this paper
• Clinical update on K-Ras targeted therapy in gastrointestinal cancers.

  2018cites this paper
• Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options

  2018cites this paper
• Combined inhibition of the PI3K/mTOR/MEK pathway induces Bim/Mcl-1-regulated apoptosis in pancreatic cancer cells

  2018cites this paper
• Pegylated Liposomal Irinotecan Hydrochloride Trihydrate for Treating Pancreatic Cancer After Gemcitabine: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

  2018cites this paper
• Population Pharmacokinetic and Exposure‐Response Analysis of Selumetinib and Its N‐desmethyl Metabolite in Patients With Non‐Small Cell Lung Cancer

  2018cites this paper
• Pharmacotherapeutic strategies for treating pancreatic cancer: advances and challenges

  2018cites this paper
• Genetics of pancreatic cancer and implications for therapy

  2018cites this paper
• Advances in Molecular Profiling and Categorisation of Pancreatic Adenocarcinoma and the Implications for Therapy

  2018cites this paper
• Biomarker-driven and molecularly targeted therapies for pancreatic adenocarcinoma.

  2018cites this paper